Sun J, et al. - Researchers coveted an examination of the safety and feasibility of Holmium laser enucleation of the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT). HoLEP exhibited similar results in patients receiving DAPT after coronary artery stunting and in patients receiving single antiplatelet (AP) therapy or non-AP therapy. It could present as a good option to the urologists for treating patients with symptomatic benign prostatic hyperplasia refractory to medical treatment.